Mainz, August 10, 2018 - The new Helmholtz Institute "HI-TRON Mainz" aims to develop effective immunotherapies and identify new biomarkers for cancer treatments.
HI-TRON is a collaboration between the German Cancer Research Center (DKFZ) and the research institute TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz. Cooperation agreements have now been signed.
"By founding of HI-TRON Mainz, we are pursuing the mission of establishing a world-leading center for personalized cancer immunotherapy. HI-TRON Mainz thus engenders the Helmholtz spirit by acting as a catalyst for groundbreaking technologies, sustainable translation of academic innovation and its clinical implementation for the benefit of patients, "so Ugur Sahin, founder and scientific director of TRON.
Mainz, August 10, 2018 – TRON is delighted to announce a Comment authored by Özlem Türeci and Ugur Sahin in the journal Nature Biomedical Engineering.
“Challenges towards the realization of individualized cancer vaccines” discusses the challenges of optimizing vaccine design, manufacturing and affordability, and identifying the most suitable clinical setting(s). TRON colleagues Martin Löwer, Barbara Schrörs and Arbel Tadmor are co-authors.
You can access this article via this link.
Mainz - TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz), a non-profit organization and internationally recognized leader in tumor immunology and cancer therapy research, has entered into a research collaboration with Astellas Pharma Inc., a company dedicated to improving the health of people through the provision of innovative and reliable pharmaceutical products.
“We are excited to collaborate with Astellas Pharma Inc. which highlights the quality of our research in oncology,” said Michael Foehlings, Managing Director of TRON. “Collaborations with key players in the pharmaceutical industry provide an excellent platform for the dissemination of research performed at TRON to address an unmet medical need and to improve patients’ lives."
Trento, Italy, June 26, 2018 - Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small fraction of patients undergo extended therapeutic responses. For prostate cancer patients whose tumors develop anti-androgen therapy resistance, further therapy has largely failed. And for cancers like Glioblastoma, pancreatic cancer, mesothelioma, small cell cancer and chemotherapy and marrow transplant-resistant acute myelogenous leukemia, a pathway to therapeutic success is not yet apparent. The thrust of this meeting will be to explore the molecular and biological sources of historical therapeutic resistance in these cancers and to assess the most promising opportunities for overcoming it.
Ugur Sahin will have a talk about 'Personalized Cancer Immunotherapy' on Tuesday June 26 during Session 4 - Therapeutically resistant Melanoma.
Further information is available at the organizer's website.
Mainz, 17. Mai 2018 - Jeder Tumor ist anders. "Krebs entsteht durch individuelle Mutationen", erklärt Prof. Dr. Ugur Sahin. "Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf die fünf Prozent, sie schauen nur auf die Gemeinsamkeit. Sie sind gezwungen zu simplifizieren und zu generalisieren. Sie packen den Krebs in Schubladen, in die er nicht gehört."
Der ganze Artikel über das Forscherpaar Özlem Türeci und Ugur Sahin, sowie seine Bestrebungen in Mainz erschien im JGU Magazin.
Mainz, June 20, 2018 - Computational Analysis becomes ever more important for the advancement of personalized medicine. Bioinformatics accelerate the patient-centric molecular characterization of diseases and lead to a deeper understanding of the underlying mechanisms thus facilitating the development of novel drugs. Progress in Artificial Intelligence has a strong impact on clinical decision making in diagnosis and treatment. Nowadays, collection of huge amounts of data in the clinic and the lab is straight forward. However, the challenge lies within the analysis to draw the right conclusion from this big data.
Dr. Martin Löwer will give an impulse talk in session 'Data analysis for disease characterization and diagnostics'
For further information prease visit the organizer's website.
TRON in the Media
Welcome to TRON
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.